cemiplimab


( Last Updated : September 9, 2021)
Generic Name:
cemiplimab
Project Status:
Pending
Therapeutic Area:
Non-small cell lung cancer
Manufacturer:
Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Libtayo
Project Line:
Reimbursement Review
Project Number:
PC0262-000
Call for patient/clinician input closed:
Tumour Type:
Lung

Details


Manufacturer Requested Reimbursement Criteria1:
For the first-line treatment of patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumor cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC and who are not candidates for surgical resection or definitive chemoradiation, or have progressed after treatment with definitive chemoradiation, or, metastatic NSCLC.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the first-line treatment of patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumor cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC and who are not candidates for surgical resection or definitive chemoradiation, or have progressed after treatment with definitive chemoradiation, or, metastatic NSCLC.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.